Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 5/20 | 0.66 |
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.61 |
| ▸ | HTR3A known ✓ | P46098 | 4/20 | 0.61 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 4/20 | 0.61 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.61 |
| ▸ | HTR1D known ✓ | P28221 | 2/20 | 0.60 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 6/20 | 0.66 |
| ▸ | HTR6 | P50406 | 5/20 | 0.61 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.61 |
| ▸ | HTR3B | O95264 | 4/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.61 |
| ▸ | HTR2C | P28335 | 4/20 | 0.61 |
| ▸ | HTR2A | P28223 | 3/20 | 0.61 |
| ▸ | THRB | P10828 | 2/20 | 0.61 |
| ▸ | HTR2B | P41595 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315894 | 0.98 | HTR7 (0.68) | HTR7HTR1AHTR6ADRB1HTR3E | |
| Hydrochloric Acid SCHEMBL11556656 | 0.96 | HTR7 (0.66) | HTR7HTR1AHTR6ADRB1HTR3E | |
| Hydrochloric Acid SCHEMBL9743614 | 0.96 | HTR7 (0.66) | HTR7HTR1AHTR6ADRB1HTR3E | |
| Bromide SCHEMBL27376788 | 0.95 | HTR7 (0.64) | HTR7HTR1AHTR6ADRB1HTR3E | |
| Hydrochloric Acid SCHEMBL12817391 | 0.90 | HTR1A (0.59) | HTR7HTR1AHTR6ADRB1HTR3E | |
| SCHEMBL20699709 | 0.84 | BPTF (0.54) | HTR7HTR1AHTTALDH1A1MAPT | |
| SCHEMBL10373948 | 0.84 | BPTF (0.54) | HTR7HTR1AHTTALDH1A1MAPT | |
| SCHEMBL4913199 | 0.82 | HTR7 (0.66) | HTR7HTR1AHTR6ADRB1HTR3E | |
| SCHEMBL255378 | 0.80 | ALDH1A1 (0.52) | HTR7HTR1ATP53HTTALDH1A1 | |
| SCHEMBL30407553 | 0.80 | BPTF (0.51) | HTR7HTR1ATP53HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713634-B2 | SEROTONIN RECEPTOR ANTAGONIST | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| US-6664251-B2 | Serotonin receptor antagonist; treating cardiovascular disorder | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| US-20030166926-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-0686632-B1 | BENZOTHIAZINE DERIVATIVE | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-20030078256-A1 | Benzothiazine derivative | SUNTORY LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-6489473-B2 | FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, ARRHYTHMIA, MYOCARDIAL INFARCTION, CONGESTIVE HEART FAILURE, CEREBRAL INFARCTION AND CEREBRAL SEQUELAE AFTER SUBARACHNOID HEMORRHAGE, HYPERTENSION | SUNTORY LIMITED (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020072515-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-0807632-B1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LTD (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-6316442-B1 | TREATMENT OF HEART DISEASE AND CEREBROVASCULAR DISTURBANCES | SUNTORY LIMITED (JP) | 2001-11-13 | — | — | US | disclosed |
| US-6258805-B1 | TREATMENT OF BRAIN DISORDERS AND HYPERTENSION | SUNTORY LIMITED (JP) | 2001-07-10 | — | — | US | disclosed |
| CN-1281854-A | Benzothiazine derivative | SUNTORY LTD (JP) | 2001-01-31 | — | — | CN | disclosed |
| CN-1058492-C | benzothiazine derivatives | SUNTORY LTD (JP) | 2000-11-15 | — | — | CN | disclosed |
| US-6001827-A | Benzothiazine derivative | SUNTORY LIMITED (JP) | 1999-12-14 | — | — | US | disclosed |
| US-5962448-A | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5874429-A | ANTIISCHEMIC AGENTS; CEREBROVASCULAR DISORDERS; CIRCULATORY IDSORDERS | SUNTORY LIMITED (JP) | 1999-02-23 | — | — | US | disclosed |
| EP-0807632-A1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LIMITED (JP) | 1997-11-19 | — | — | EP | disclosed |
| CN-1119859-A | benzothiazine derivatives | SUNTORY LTD (JP) | 1996-04-03 | — | — | CN | disclosed |
| EP-0686632-A1 | BENZOTHIAZINE DERIVATIVE | SUNTORY LIMITED (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072515-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | HTR1A 6/4885ADRB1 89/4885HTR3A 11/4885 |
| US-20030166926-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | HTR1A 7/4885ADRB1 83/4885HTR3A 12/4885 |
| US-20030078256-A1 | Benzothiazine derivative | TPH2, ADRB2, TPH1 | HTR1A 7/4885ADRB1 10/4885HTR3A 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.